Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nesina (alogliptin) long‑term specified drug-use survey in type 2 diabetes mellitus with inadequate response to insulin or rapid-acting insulin secretagogues
jRCT1080222558Completed
- Sponsor
- Takeda
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of alogliptin in type 2 diabetes mellitus (T2DM), sponsored by Takeda. Primary endpoint: Safety of long-term Nesina use in combination with hypoglycemic agents. Started Jul 2014; status: completed.
02
Drugs
alogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT1080222558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080222558.